【Breaking News】 Haibu Pharma™ ceutical appeared at ∑♥the 89th China International Pharmaceu≤ ∑tical Raw Materials/Inte★βλrmediates/Packaging/Equipmen ±§t Trade Fair (API Chin✔♣a)
Classification:
Company News
Release time:
2023-10-24
On October 18, 2023, the 89th China I£★₩£nternational Pharmaceutical Raw Materia×₽λ↓ls/Intermediates/Packaging/Equipment Tr≥•♣ade Fair (API China) a♠φnd the 27th China Inter"♦national Pharmaceuti ₽cal (Industrial) Exhibition and Tσ∑$λechnology Exchange Conference (CHINA≈£λ-PHARM) opened at the Nanjing ε↑≠•International Expo Center, lastingε for three days.
"Haibu Pharmaceutical" Building D↔"∑£reams Together
Meeting at the right time, aπ↔> new chapter is written in time! Aφ₩•γt the exhibition site, the↑>¶ Haibu API business team actively c₽£∑σommunicated and negotiated≠ ∑® with new and old cust ≠αomers to understand i♥φndustry development trends, cutting-e↓↓dge technologies, etc., and conduct∏×σed in-depth discussions on mar≤☆®ket information, produc∏t information, and b•φ¶✘usiness cooperation. The team's e☆≤Ωnthusiastic and professional serv<•☆ice received high recα☆>ognition from both new and old cust>₹omers, laying a solid→♥¶ foundation for futur±≈♦e cooperation.
This exhibition achieved zero-dis✘εtance contact between products, technol←"ogies, and customers, providing♥↑ new ideas and directions &λfor future upgrades of Ha∞ ↔ibu Pharmaceutical's p®±"roduct quality and service qua÷£<lity.
In the future, Haibu P'÷harmaceutical will actively participatδ ×e in international exhibiσtions to improve its global marketing n•etwork construction. γ₹≈∑With a more mature and professional✘δ service attitude, it will provide v ✔♠arious services such as raw matγ☆erial drug-related declara₽λ>tions, commercial supply of &→λpharmaceutical intermediates, C • RO services for raw mδδaterials and formulations, joi→"&£nt MAH licensing services, etc. ₹¶We look forward to since re cooperation with industry colleague↓•α☆s to contribute to the prosperous deεα®velopment of the pharma₽>ceutical industry.
Beijing Haibu Pharmaceutical Technolo×♦gy Co., Ltd. (referred to asγ¥ε "Haibu Pharmaceutical") was esta≠σΩ₹blished in 2005. It is a high-tech₩ enterprise with "chemical ★←σdrug research and development" as its ★★core capability. It has a research cent¶ •αer in Beijing, a pilot ve← πrification center for₩< raw materials and fo∞☆rmulations, and a GMP indu✔π¶strial production base. The compa♥αny mainly engages in CRO serviceδs for raw materials and formulations♥≤↑, joint MAH licensing serv∑×ices, raw material dru←♣g-related declarations, a≈∑s well as commercial supply of pha∏♥∏rmaceutical intermediates. Its £>≠∑R&D products cover mul♥ tiple therapeutic areas includ☆₽ing anti-tumor, anti-depressio<×¥n, anti-epilepsy, anti-anxiety, cardiπ ovascular diseases, dig★÷™estive system diseases, respiratory s↕ε ystem diseases.
Haibu Pharmaceutical←σ has been awarded the title of § "Top 20 Chinese Pharmaceutical R&±♦;D Companies" for several 'consecutive years and has been ↑βrecognized as a "Specializ¶φed & Innovative EΩ™'nterprise" by Beijing City; it is aε<™₹lso designated as a "Natio ★©↓nal High-tech Enterpri™ε±←se," "Beijing Science &→φ Technology Research Developme≤÷nt Institution," "Beijing Yizhuang Entεδerprise Innovation Center," among oth©""ers.
Beijing Hope Pharmaceγ£₹utical Co., Ltd.
